Vappu Rantalaiho

Summary

Affiliation: University of Tampere
Country: Finland

Publications

  1. pmc Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
    Vappu Rantalaiho
    Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI 33521 Tampere, Finland
    Arthritis Res Ther 12:R122. 2010
  2. doi request reprint The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial
    Vappu Rantalaiho
    Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
    Arthritis Rheum 60:1222-31. 2009
  3. ncbi request reprint Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis
    Vappu Rantalaiho
    Tampere University Hospital, Tampere, Finland
    Clin Exp Rheumatol 30:S27-31. 2012
  4. doi request reprint Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NE
    Vappu Rantalaiho
    Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
    Ann Rheum Dis 73:1954-61. 2014
  5. doi request reprint Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomize
    Vappu Rantalaiho
    From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital Fimlab Laboratories, Tampere Unit of Primary Health Care Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital Department of General Practice Institute of Clinical Medicine, University of Helsinki Orton Hospital, Helsinki Unit of Primary Health Care Department of Medicine, Kuopio University Hospital, Kuopio Medcare Foundation, Äänekoski Department of Medicine, Seinajoki Central Hospital, Seinäjoki Department of Medicine, Jyvaskyla Central Hospital, Jyväskylä Department of Rheumatology, Satakunta Central Hospital, Rauma Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku Department of Medicine, Oulu University Hospital, Oulu Central Hospital of Lapland, Rovaniemi, Finland V Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital H Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital S Järvenpää, 11-43 Bath Street
    J Rheumatol 41:2379-85. 2014
  6. ncbi request reprint Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial
    K L Karstila
    Tampere University Hospital, and Medical School, University of Tampere, Tampere, Finland
    Clin Exp Rheumatol 28:73-8. 2010

Detail Information

Publications6

  1. pmc Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
    Vappu Rantalaiho
    Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI 33521 Tampere, Finland
    Arthritis Res Ther 12:R122. 2010
    ..The aim of this study was to evaluate the radiologic progression beyond that time in patients with early RA initially treated with a combination of three disease-modifying antirheumatic drugs (DMARDs) or a single DMARD...
  2. doi request reprint The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial
    Vappu Rantalaiho
    Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
    Arthritis Rheum 60:1222-31. 2009
    ..To evaluate the evolution of functional and clinical outcomes over 11 years in patients with early rheumatoid arthritis (RA) initially treated with a combination of 3 disease-modifying antirheumatic drugs (DMARDs) or with a single DMARD...
  3. ncbi request reprint Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis
    Vappu Rantalaiho
    Tampere University Hospital, Tampere, Finland
    Clin Exp Rheumatol 30:S27-31. 2012
    ..As a consequence, the use of biologics in early RA is less frequent in Finland compared to many countries. Simultaneously, however, at least one hard outcome of RA, work disability, has decreased...
  4. doi request reprint Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NE
    Vappu Rantalaiho
    Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
    Ann Rheum Dis 73:1954-61. 2014
    ..To study whether adding initial infliximab to remission-targeted initial combination-DMARD treatment improves the long-term outcomes in patients with early rheumatoid arthritis (RA)...
  5. doi request reprint Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomize
    Vappu Rantalaiho
    From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital Fimlab Laboratories, Tampere Unit of Primary Health Care Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital Department of General Practice Institute of Clinical Medicine, University of Helsinki Orton Hospital, Helsinki Unit of Primary Health Care Department of Medicine, Kuopio University Hospital, Kuopio Medcare Foundation, Äänekoski Department of Medicine, Seinajoki Central Hospital, Seinäjoki Department of Medicine, Jyvaskyla Central Hospital, Jyväskylä Department of Rheumatology, Satakunta Central Hospital, Rauma Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku Department of Medicine, Oulu University Hospital, Oulu Central Hospital of Lapland, Rovaniemi, Finland V Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital H Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital S Järvenpää, 11-43 Bath Street
    J Rheumatol 41:2379-85. 2014
    ..Here we aim to identify the patients failing these targets even after aggressive treatment...
  6. ncbi request reprint Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial
    K L Karstila
    Tampere University Hospital, and Medical School, University of Tampere, Tampere, Finland
    Clin Exp Rheumatol 28:73-8. 2010
    ..To evaluate the renal safety of traditional disease-modifying antirheumatic drugs (DMARDs) in early rheumatoid arthritis (RA)...